In recent years, Heart Failure with Improved Ejection Fraction (HFimpEF) has developed into a clinical entity in its own right, which is being considered in an increasingly differentiated manner. With the growing number of available disease-modifying therapies, the number of patients whose systolic function recovers under guideline-compliant therapy is also increasing. The term HFimpEF covers the group that initially had a left ventricular ejection fraction (LVEF) ≤40% and increased to >40% under therapy, accompanied by clinical improvement. A recent study clearly defines that this is not a “cure”, but a form of remission with structural and molecular “memory” of the disease. This finding forms the starting point for a disease model that takes into account both improvements and relapses and thus has direct therapeutic consequences.
Jetzt beitreten
